Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Emerging therapeutic approaches, such as targeted immune boosting therapies, non‑coding RNA‑based therapies, probiotics, natural products, oncolytic viral therapies, and biomarker‑driven therapies, have shown promising results in preclinical and clinical studies.
Colorectal cancer (CRC) affects 1 in 23 males and 1 in 25 females, making it the third most common cancer.... Emerging therapeutic approaches, such as targeted immune boosting therapies, non‑coding RNA‑based therapies, probiotics, natural products, oncolytic viral therapies, and biomarker‑driven therapies, have shown promising results in preclinical and clinical studies.
A vast literature of patient data has revealed that conventional therapies are non‑specific and have numerous secondary complications, and patients develop resistance to conventional chemotherapies. There is a need to develop novel CRC therapies that render resistant tumors more sensitive to chemotherapeutic drugs.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
- Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure